Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Recruiting · NCT06096038 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, head and neck cancer, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 | 2026-09-16 | NCT06096038 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bellicum Pharmaceuticals | 12 |
| M.D. Anderson Cancer Center | 1145 |
| National Cancer Institute (NCI) | 3015 |
| UNC Lineberger Comprehensive Cancer Center | 125 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill | Chapel Hill | United States | 3 |